TTrialPathMatch Me to Trials
← Back to trials
RecruitingRefractory and/or Relapsed Metastatic Solid Tumors

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Eligible age

1–50 yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Where it's recruiting

Maryland

Baltimore

New York

The Bronx · Valhalla

Source: ClinicalTrials.gov · NCT01804634 · last updated 2026-03-13

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors · TrialPath